Leading Chinese Drug Researcher Calls for Greater Transparency on China Vaccines

China’s Covid-19 vaccines may have won approval in a dozen countries for emergency use, but the failure to publish detailed trial data could undermine public trust, a leading researcher said in an interview.

Ding Sheng, dean of Tsinghua University’s School of Pharmaceutical Sciences and director of the Global Health Drug Discovery Institute (GHDDI), called for the original clinical trial data from Chinese experimental vaccines to be made public so that experts can better assess their efficacy and eliminate lingering safety concerns which have emerged in China and abroad.